This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Lepirudin in Treating Patients With Recurrent or Advanced Small Cell Lung Cancer

This study has been terminated.
(Study funding was dropped.)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Dartmouth-Hitchcock Medical Center Identifier:
First received: November 1, 1999
Last updated: June 27, 2016
Last verified: June 2016

RATIONALE: Anticoagulants, such as lepirudin, may help prevent blood clots from forming in patients who have received chemotherapy for small cell lung cancer.

PURPOSE: This phase I/II trial is studying the side effects and best dose of lepirudin in treating patients with recurrent or advanced small cell lung cancer.

Condition Intervention Phase
Lung Cancer Biological: lepirudin Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Recombinant Desulfato Hirudin, Lepirudin (Refludan) in Small Cell Lung Cancer Patients Previously Treated With Chemotherapy

Resource links provided by NLM:

Further study details as provided by Dartmouth-Hitchcock Medical Center:

Primary Outcome Measures:
  • Dose, Safety and Antitumor Response Rate of Administering Recombinant Desulfato Hirudin, Elpirudin to Previously Treated Patients With Extensive or Recurrent Small Cell Lung Cancer [ Time Frame: 18 months ]
    Evaluated through clinical exams, tumor assessments, laboratory assessment, and adverse event assessments.

Enrollment: 1
Study Start Date: November 1998
Study Completion Date: July 2001
Primary Completion Date: July 2001 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lepirudin
Dose level 1: 10 mg once daily -> (total dose, 10 mg/d) Dose level 2: 15 mg once daily -> (total dose, 15 mg/d) Dose level 3: 10 mg twice daily -> (total dose, 20 mg/d) Dose level 4: 15 mg twice daily -> (total dose, 30 mg/d) Dose level 5. 20 mg twice daily -> (total dose, 40 mg/d) Dose level 6: 25 mg twice daily -> (total dose, 50 mg/d)
Biological: lepirudin

Detailed Description:

OBJECTIVES: I. Determine the dose, safety, and antitumor response rate of lepirudin in patients with recurrent or extensive stage small cell lung cancer previously treated with chemotherapy.

OUTLINE: This is a dose escalation (in individual patients) study. Patients receive dose escalated lepirudin subcutaneously once or twice a day for 3-4 days. Dose escalation continues in each patient until aPTT prolongation occurs or the maximum dose level is reached. The patient then continues treatment on the maximum tolerated dose. Treatment continues in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 20-35 patients will be accrued for this study within 18-24 months.


Ages Eligible for Study:   18 Years to 120 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  1. Pathologically confirmed recurrent or extensive stage small cell lung cancer.
  2. Received at least one prior chemotherapy regimen
  3. Measurable or evaluable disease that has not been irradiated
  4. No pleural effusions, bone metastases, brain metastases, elevated serum enzymes, or radionuclide scans as the sole indicator lesion
  5. Brain metastases allowed if patients received cranial irradiation and have no clinical evidence of brain metastases


  1. Age: Not specified
  2. Performance status: Karnofsky 60-100%
  3. Life expectancy: Not specified
  4. Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3
  5. Hepatic: Bilirubin no greater than 2.0 mg/dL PT and aPTT normal
  6. Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance greater than 60 mL/min
  7. Cardiovascular: No unstable heart rhythm No unstable angina No clinical evidence of congestive heart failure No prior cerebrovascular accident or stroke No uncontrolled or severe hypertension
  8. Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception
  9. At least 6 weeks since any signs or symptoms of bleeding No history of bleeding disorder
  10. No bacterial endocarditis or other active infection


  1. Biologic therapy: Not specified
  2. Chemotherapy: At least 3 weeks since prior chemotherapy
  3. Endocrine therapy: Not specified Radiotherapy: At least 3 weeks since prior radiotherapy
  4. Surgery: At least 6 weeks since major surgery, trauma, or needle biopsy of any organ
  5. Other: No concurrent anticoagulant or platelet inhibitor therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00003726

United States, New Hampshire
Norris Cotton Cancer Center
Lebanon, New Hampshire, United States, 03756
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
Study Chair: James R. Rigas, MD Norris Cotton Cancer Center
  More Information

Responsible Party: Dartmouth-Hitchcock Medical Center Identifier: NCT00003726     History of Changes
Other Study ID Numbers: D9815
P30CA023108 ( US NIH Grant/Contract Award Number )
DMS-9815 ( Other Identifier: Dartmouth-Hitchcock Medical Center )
NCI-V98-1512 ( Other Identifier: NCI )
Study First Received: November 1, 1999
Results First Received: May 16, 2013
Last Updated: June 27, 2016

Keywords provided by Dartmouth-Hitchcock Medical Center:
extensive stage small cell lung cancer
recurrent small cell lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Small Cell Lung Carcinoma
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Fibrinolytic Agents
Fibrin Modulating Agents processed this record on June 22, 2017